Regulatory milestones

Epigenomics AG (Xetra:ECX) fell €2.62 (42%) to €3.69 last week after saying it received a response letter from FDA for a PMA for its Epi proColon 2.0 blood-based colorectal cancer (CRC) screening test. The company said FDA requested additional data demonstrating the test would increase compliance for CRC screening in patients who do not undergo screening by recommended methods.